Cases & Deals

Celgene invests in and enters into strategic collaboration with NantBioScience

Clients Celgene Corporation

Jones Day represented Celgene Corporation, a biopharmaceutical company, in connection with its purchase of $75 million of Series A Preferred Stock in a private placement by NantBioScience, a subsidiary of NantWorks, LLC and a biopharmaceutical company focused on the discovery of innovative treatments by developing molecularly targeted drugs. Celgene and NantBioScience concurrently entered into a strategic collaboration to advance research programs to benefit cancer patients in need of new therapeutic solutions.